In 2025, Sapphire RX was honored with an Outstanding Achievement Award in Modern Wellness Care, recognizing its commitment to advancing secure and compassionate telehealth services. This ...
Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les ...
Cleveland, Ohio, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public impact investing company dedicated to acquiring, reclaiming and ...
TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and ...
The Company will use the proceeds of the First Tranche of the Offering towards advancing its Alzheimer’s Disease (“ AD ”) program including the opening of its first U.S. AD clinic, general and ...
In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 150,000 shares at the public offering price, less the underwriting discounts and commissions.
Predictive Oncology (Nasdaq: POAI) , an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir ...
COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that Peter H.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2025 operating and financial results and reviewed recent ...
Following review of the positive interim clinical study results from the Phase 1b/2a trial of BB-301, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to BB-301 for the ...
A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns ...
A total of 200,000 Fagron shares have been repurchased under the buy-back program at an average price of € 20.6805 per share, corresponding to a total amount of € 4,136,093.00. The share buy-back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback